key: cord-0330945-r8p4jikf
authors: Wey, E. Q.; Bristow, C.; Nandani, A.; O'Farrell, B.; Pang, J.; Lanzman, M.; Yang, S.; Ho, S.; Mack, D.; Spiro, M.; Balakrishnan, I.; Bhagani, S.; Pollara, G.
title: Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19
date: 2021-07-07
journal: nan
DOI: 10.1101/2021.07.03.21259949
sha: 3bfe350d1415191fc78a0e4c924b30b82e055005
doc_id: 330945
cord_uid: r8p4jikf

C-reactive protein (CRP) levels are elevated following bacterial infections but may be attenuated by the IL-6-receptor antagonist tocilizumab. In hospitalised COVID-19 patients, tocilizumab induced a transient (<21 day) fall in CRP but retained CRP responses to nosocomial blood stream infections, and therefore its utility in guiding antibiotic prescribing.

Bacterial co-infection in COVID-19 is infrequent and challenging to exclude [1,2], but occurs more commonly 30 in longer hospital stays and following admission to the intensive care unit (ICU) [3] . This dichotomy emphasises 31 the role of biomarkers to both diagnose bacterial co-infection, guiding appropriate antibiotic use, as well as 32 support withholding unnecessary antibiotics to minimise selection for antimicrobial resistance. 33

Elevations in C-reactive protein (CRP) concentration are commonly taken to indicate bacterial infections, but 34 many factors promote secretion of this acute phase response protein, including increases in circulating IL-6 35 cytokine [1] . Severe COVID-19 is characterised by a hyperinflammatory state partly driven by elevated IL-6 36 activity, as demonstrated by the mortality benefit offered by tocilizumab, a humanised monoclonal antibody 37 targeting the IL-6 receptor [4, 5] . 38

One consequence of tocilizumab-mediated inhibition of the IL-6 signalling pathway is that routinely measured 39 CRP concentrations are decreased [6] . In inflammatory arthritides, tocilizumab doses are administered every 40 2-4 weeks, resulting in variable attenuation of CRP responses to bacterial infection [7] [8] [9] . In COVID-19, single 41 doses of tocilizumab are used [4, 5] , making the extent and duration of IL-6 signalling suppression less defined 42 [10] . In a small COVID-19 cohort with blood stream infections (BSIs) that had received tocilizumab, CRP 43 concentrations were reduced at the time of BSI diagnosis, but remained above normal values [ . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 7, 2021. 

We identified 107 patients admitted to RFH with COVID-19 who received tocilizumab as part of routine clinical 74 care or within the context of randomised clinical trials. Of these individuals, 17 developed a BSI during their 75 hospital admission (table S1). We also identified a comparator group of 55 patients with COVID-19 who did 76 not receive tocilizumab but that developed a BSI during their hospital admission (table S1). Tocilizumab use 77 was more commonly associated with ICU admission, but the range of organisms responsible for BSI was 78 comparable between the groups (table S1). 79

To assess the impact of tocilizumab on inflammatory marker dynamics, we derived CRP concentrations and 80 white cell counts over time in tocilizumab recipients. As expected, CRP fell rapidly in the first week after 81 tocilizumab administration (fig 1A) , whereas this was not observed for total white cell, neutrophil or 82 lymphocyte counts ( fig 1A & fig S1) . The reduction in CRP following tocilizumab was short lived, however, 83

patients showing a rise in CRP concentration within 21 days of receiving the drug ( fig 1A) . To exclude 84 confounding by bacterial co-infection, we performed a sensitivity analysis on 90 patients that did not develop 85 a BSI following receipt of tocilizumab, and an early reduction followed by rebound in CRP was still observed 86 S2A) . A similar pattern was evident in patients that developed a BSI, although notably CRP concentrations 87 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. severe COVID-19. First, false reassurance from the lack of CRP increments in confirmed BSIs occurs no more 116 frequently than in the absence of tocilizumab, reducing the risk that tocilizumab use would delay the 117 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.03.21259949 doi: medRxiv preprint prescription of indicated antibiotics. Second, low CRP levels in tocilizumab recipients is not an indication for 118 continued prescription of unnecessary antibiotics, supporting antimicrobial stewardship efforts in this cohort 119 of patients. Nevertheless, it was notable that BSI onset did not initiate CRP elevations in all patients, 120 independent of prior tocilizumab use, emphasising that CRP should be only one of several variables that are 121 used to diagnose incipient bacterial infections. 122

Despite preserved CRP responses to BSI, tocilizumab use did reduce baseline CRP concentrations. However, 123 this effect was transient, CRP levels recovering at varying times, mostly within 3 weeks. In addition, increments 124 in CRP after BSI onset were not related to the time since tocilizumab administration, indicating that CRP 125 increment is unlikely to be solely IL-6 dependent or that in COVID-19 neutralisation of the IL-6 axis by a single 126 tocilizumab dose is not absolute. Measuring IL-6 signalling activity in vivo may predict attenuation of CRP 127 responses in some individuals, as well as inform the need for further tocilizumab dosing in COVID-19 [10]. 128

Our study has limitations. The single-centre, retrospective source of our clinical data constrained numbers of 129 patients that could be identified in each group, negating the ability to correct for potential confounders. 

We declare that all authors have no conflicts of interest 142 143 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.03.21259949 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.03.21259949 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.03.21259949 doi: medRxiv preprint

Exclusion of bacterial co-infection in COVID-19 using baseline 158 inflammatory markers and their response to antibiotics

Bacterial co-infection and secondary infection in patients with 160

COVID-19: a living rapid review and meta-analysis

Co-infections, secondary infections, and antimicrobial use in 162 patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a 163 multicentre, prospective cohort study

Interleukin-6 Receptor Antagonists in 165